Pharmaceutical interventions for weight-loss maintenance: no effect from cabergoline.

Area of Science:

• Obesity research
• Neuroendocrinology
• Metabolic health

Background:

• Weight regain is a significant challenge in obesity management.
• Dopamine receptor stimulation is linked to weight regulation.
• Previous studies suggest a role for dopamine in controlling body weight.

Purpose of the Study:

• To investigate if dopamine agonist treatment can prevent weight regain in obese individuals post-weight loss.
• To test the hypothesis that stimulating central nervous system dopamine receptors aids weight maintenance.

Main Methods:

• A 2-year, double-blind, randomized controlled trial.
• Compared cabergoline (dopamine agonist) with placebo in obese individuals who lost at least 5% body weight.
• Primary outcome: difference in mean weight between groups over 24 months.

Main Results:

• No significant difference in body weight between cabergoline and placebo groups at 24 months (0.6 kg difference).
• Mean weight regain was 5.1 kg in both groups.
• No significant differences observed in BMI, waist circumference, or metabolic parameters.

Conclusions:

• Cabergoline treatment does not prevent weight regain in obese individuals following a structured weight loss program.
• Dopamine agonist therapy is not effective for long-term weight maintenance in this population.